10-Q: Quoin Pharma Q3 2025: Losses Mount, Capital Secured

Quoin Pharmaceuticals reports increased Q3 2025 net losses and cash burn, but secures $19.9 million in new capital and gains FDA Orphan Drug Designation for QRX003.

Summary

• Net loss for the nine months ended September 30, 2025, increased to $11.5 million from $6.7 million in the prior year.
• Operating expenses rose significantly, with Research and Development (R&D) expenses increasing by 163% to $6.7 million for the nine months ended September 30, 2025.
• The company had an accumulated deficit of approximately $66.6 million as of September 30, 2025.
• Cash and cash equivalents stood at $1.8 million, and investments at $3.6 million, as of September 30, 2025.
• Subsequent to the quarter, Quoin secured approximately $16.6 million in gross proceeds from a private placement and an additional $3.3 million from warrant exercises, totaling $19.9 million.
• QRX003, the lead product for Netherton Syndrome, is in two pivotal registrational clinical studies in the US, Middle East, UK, and Europe.
• The FDA granted Orphan Drug Designation to QRX003 for Netherton Syndrome in October 2025, following EMA designation in May 2025.
• The company discontinued its Netherton Syndrome research program with Queensland University of Technology (QUT) in July 2025.
• Shareholders approved an increase in authorized ordinary share capital from 100 million to 5 billion and adopted a new 2025 Equity Incentive Plan.

Sentiment

Score: 4

Explanation: While the company continues to incur significant losses and negative cash flow, the successful private placement and warrant exercises provide crucial funding for at least the next 12 months. The FDA and EMA Orphan Drug Designations for QRX003 are significant positive regulatory milestones that de-risk the lead product's path to market and offer future commercial benefits. However, the substantial dilution from the capital raise and the ongoing need for future financing temper the positive sentiment.

Positives

• Secured approximately $16.6 million in gross proceeds from a private placement on October 10, 2025, and an additional $3.3 million from warrant exercises on October 14, 2025, significantly improving liquidity.
• The FDA granted Orphan Drug Designation to QRX003 for Netherton Syndrome on October 21, 2025, providing potential benefits like tax credits, fee waivers, and seven years of market exclusivity if approved.
• The European Medicines Agency (EMA) also granted Orphan Drug Designation to QRX003 in May 2025.
• Regained compliance with Nasdaq's Minimum Bid Price Requirement on April 29, 2025, following a 1-for-35 reverse split.
• Expanded QRX003 clinical trials internationally to the Middle East, United Kingdom, Spain, Germany, and Austria.
• Established 9 commercial partnerships for QRX003 spanning 61 countries outside of core commercial territories.
• Initiated development of QRX003 for Peeling Skin Syndrome, with the first subject treated in New Zealand.
• Entered into a research agreement with University College Cork (UCC) for novel topical rapamycin formulations for other rare diseases, with funding up to approximately $665,000 plus VAT over 2.5 years.

Negatives

• Net loss for the three months ended September 30, 2025, increased to $3,948,165 from $2,349,885 in the same period last year, a 68% increase.
• Net loss for the nine months ended September 30, 2025, increased to $11,456,282 from $6,651,198 in the same period last year, a 72% increase.
• Cash and cash equivalents decreased from $3,623,343 at December 31, 2024, to $1,830,906 at September 30, 2025.
• Investments decreased from $10,433,535 at December 31, 2024, to $3,581,772 at September 30, 2025.
• Accumulated deficit grew to $66,622,074 at September 30, 2025, from $55,165,792 at December 31, 2024.
• Negative cash flow from operations increased to $8,505,969 for the nine months ended September 30, 2025, from $5,620,790 in the prior year.
• Shareholders' equity (deficit) turned negative, from $9,204,673 at December 31, 2024, to $(1,214,620) at September 30, 2025, indicating a precarious financial position before the subsequent capital raise.
• Significant dilution for existing shareholders due to the recent private placement and warrant exercises.
• Discontinuation of the Netherton Syndrome research program with QUT in July 2025.

Risks

• Limited operating history and a history of losses, with an inability to fund the business from operations, requiring additional capital that may not be available on acceptable terms.
• Lack of revenue and potential inability to achieve profitability.
• Uncertainties of cash flows and potential inability to meet working capital needs.
• Ability to obtain regulatory approvals for product candidates.
• Ability to generate favorable pre-clinical and clinical trial results, with potential for additional costs or delays from unsuccessful trials.
• Inability to predict the timing of revenue from sales of a future product.
• Extensive regulatory requirements and future developmental and regulatory challenges even if product approval is obtained.
• Ability to maintain orphan drug designation or data exclusivity.
• Manufacturing processes may not be validated or accepted by the scientific community.
• Difficulties enrolling patients in clinical trials.
• Requirements of being a publicly traded company may strain resources.
• Potential adverse effects from failure to maintain effective internal controls.
• Ability to comply with Nasdaq's continued listing requirements, specifically the stockholders' equity requirement, and the risk of delisting if compliance is not maintained.
• Potential negative impact on securities price and trading volume if analysts do not publish reports or change recommendations adversely.
• Potential volatility of the market price for ADSs.
• Potential dilution of shareholders' ownership due to future issuances of share capital.
• Dependence on several third-party suppliers, including single-source suppliers for clinical studies management, active pharmaceutical ingredient (API), and drug product manufacturing.
• Inadequate funding for FDA, SEC, and other government agencies, including from government shutdowns, could hinder their ability to perform normal business functions, impacting the business.
• Limits on the ability to sell securities under the Purchase Agreements from the October 2025 private placement, including standstill periods and restrictions on pricing, which may affect future financing options.

Future Outlook

The company expects to continue incurring significant expenses and increasing operating losses as it advances QRX003 through late-stage clinical development, prepares for regulatory approval and commercialization, and potentially expands its pipeline. It does not anticipate generating revenue from product sales until successful development and marketing approval, which is expected to take several years and is subject to significant uncertainty. Additional financing will be required to fund operations until commercial profitability is achieved, if ever. The company believes it has sufficient cash and liquidity for at least one year from the filing date, considering the recent capital raise.

Management Comments

• Our mission is to develop and commercialize proprietary therapeutic drug products that treat rare and orphan diseases, particularly those where none currently exists.
• We do not expect to generate revenue from product sales unless and until we successfully complete development and obtain marketing approval for one or more of our product candidates, which we expect will take a number of years and is subject to significant uncertainty.
• Accordingly, we will need to raise additional capital prior to the commercialization of QRX003 or any other product candidate.
• Based upon the Company's current business plans and cash, cash equivalents and investments on hand as at the date of issuance of these financial statements, management has concluded that the Company has sufficient cash and liquidity to continue as a going concern for a period of at least one year from the issuance of the unaudited consolidated financial statements included in this report.

Industry Context

Quoin Pharmaceuticals operates in the highly specialized and capital-intensive biopharmaceutical sector, specifically targeting rare and orphan diseases. This niche often benefits from regulatory incentives like Orphan Drug Designation, which provides market exclusivity and other benefits, crucial for companies with limited pipelines. The company's strategy of pursuing late-stage clinical development for QRX003 and expanding trials internationally aligns with typical biopharma growth strategies to maximize market reach and potential revenue. The reliance on third-party Contract Research Organizations (CROs) and manufacturers is common for smaller biotechs to manage high R&D costs and specialized expertise. The significant cash burn and need for continuous capital raises are characteristic of development-stage pharmaceutical companies prior to commercialization.

Comparison to Industry Standards

• The company's accumulated deficit of $66.6 million and consistent net losses are typical for a late-stage clinical biopharmaceutical company that has not yet commercialized any products. For example, many small-cap biotech firms like Avalo Therapeutics or Ardelyx have reported similar financial profiles during their development phases, characterized by high R&D expenditure and negative cash flows.
• The increase in R&D expenses by 163% for the nine months ended September 30, 2025, to $6.7 million, reflects a common industry trend of escalating costs as product candidates advance into pivotal registrational clinical studies, which are inherently more expensive due to larger patient cohorts and longer durations. This is comparable to the R&D ramp-up seen in companies like Krystal Biotech during the late-stage development of their rare disease therapies.
• The successful securing of $19.9 million in new capital through a private placement and warrant exercises is a standard financing mechanism for pre-revenue biotechs to extend their cash runway and fund ongoing clinical programs. This is a common practice, similar to recent capital raises by Travere Therapeutics or BridgeBio Pharma to support their rare disease pipelines.
• The receipt of FDA and EMA Orphan Drug Designations for QRX003 for Netherton Syndrome is a significant regulatory milestone, providing a competitive advantage and potential market exclusivity. This is a critical achievement for rare disease drug developers, akin to the designations received by Sarepta Therapeutics for Duchenne muscular dystrophy treatments, which can significantly de-risk future commercialization.
• The company's strategy to establish its own sales infrastructure in core territories (US, Europe, Japan) while partnering for other regions (61 countries) is a hybrid commercialization model often adopted by smaller biotechs to balance direct market control with broader global reach, similar to approaches taken by companies like Amicus Therapeutics for their rare disease portfolio.

Corporate Governance

Legal Proceedings

• The company is currently not a party to any material legal or administrative proceedings and is not aware of any pending or threatened material legal or administrative proceedings against it.

Related Party Transactions

• The company owes approximately $1.4 million to Dr. Myers (CEO) and $1.0 million to Ms. Carter (CFO) as of September 30, 2025, for accrued compensation and expenses from prior to the Merger.
• The company repaid $225,000 to Dr. Myers and $225,000 to Ms. Carter in the nine months ended September 30, 2025, as part of monthly $25,000 payments to each.
• Two of the three remaining 2020 Noteholders, to whom an estimated liability of $1,146,000 is due, are related parties, with an aggregate estimated liability of $339,000 as of September 30, 2025.
• Dennis Langer, a director, participated in the October 2025 private placement, purchasing 15,152 ADSs and accompanying Ordinary Warrants for approximately $128,641.

Stakeholder Impact

• Shareholders: Significant dilution from the recent private placement and warrant exercises. Potential for further dilution from future capital raises and the new equity incentive plan. Risk of delisting from Nasdaq if stockholders' equity requirements are not met, which would negatively impact liquidity and share price.
• Employees: Stock-based compensation is a significant component of remuneration, and the new 2025 Equity Incentive Plan provides for continued awards. Severance costs contributed to increased general and administrative expenses.
• Customers (future): Continued clinical development of QRX003 and other product candidates aims to provide treatments for rare and orphan diseases where options are limited or non-existent.
• Suppliers/Partners: Dependence on third-party suppliers for clinical studies, API, and manufacturing, as well as commercial partners for global distribution, indicates reliance on external relationships for operational success.
• Creditors: The company has outstanding indebtedness to officers and 2020 Noteholders, which are being repaid or are accrued liabilities.

Next Steps

• Complete late-stage clinical testing of QRX003 in Netherton Syndrome.
• If successful, file for marketing approval for QRX003 in the United States, Europe, Japan, and other territories with commercial agreements.
• Prepare to commercialize QRX003 by establishing sales infrastructure in the U.S., Europe, and Japan, and leveraging distribution partnerships in other territories.
• Expand the QRX003 study for pediatric NS patients to include two additional children in Austria and potentially in Spain, the United Kingdom, and other countries.
• Expand the QRX003 study for Peeling Skin Syndrome to include up to three additional pediatric subjects.
• Schedule a meeting with QUT to discuss the future direction of the Scleroderma research program.
• Advance the clinical development of rapamycin formulations developed by UCC, following completion of the research program.
• Pursue business development activities, including partnering, licensing, merger, and acquisition opportunities to expand the pipeline.
• Maintain compliance with Nasdaq listing requirements, particularly the stockholders' equity requirement.

Key Dates

Recommendation

Quoin Pharmaceuticals is a high-risk, high-reward development-stage biopharmaceutical company. While the significant net losses and negative shareholders' equity at the reporting date are concerning, the subsequent capital raise of nearly $20 million provides a critical lifeline and extends the operational runway for at least 12 months. The FDA and EMA Orphan Drug Designations for QRX003 are substantial positive regulatory milestones that de-risk the lead asset and offer significant market exclusivity potential. However, the company remains pre-revenue, faces substantial R&D costs, and will require further financing. The recent capital raise also resulted in significant dilution. Given the binary nature of clinical development outcomes and the company's early stage, a "Hold" recommendation is appropriate for investors who are already exposed and believe in the long-term potential of QRX003, while acknowledging the inherent risks and the need for continued monitoring of clinical progress and financial stability. New investors should approach with extreme caution due to the high risk profile.

Keywords

Netherton Syndrome, Orphan Drug Designation, QRX003, Biopharmaceutical, Clinical Trials, Rare Diseases, SEC Filing, Private Placement, Nasdaq Listing, Scleroderma, Peeling Skin Syndrome, Rapamycin, Drug Development